Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Genomic signatures in breast cancer patients significantly altered treatment decisions for 30.7% of individuals. These tests helped determine chemotherapy necessity, guiding oncologists in adjuvant therapy choices.
Area Of Science
- Oncology
- Genomics
- Medical Diagnostics
Background
- Adjuvant chemotherapy decisions in breast cancer are complex.
- Genomic signatures offer personalized risk assessment.
- Evaluating the real-world impact of these signatures is crucial.
Purpose Of The Study
- To assess the role and impact of genomic signatures on treatment decisions for breast cancer patients.
- To analyze how genomic signatures influence the indication or contraindication of adjuvant chemotherapy.
Main Methods
- Retrospective study of 50 breast cancer patients from a private oncology clinic (Nov 2014 - Feb 2021).
- Included patients with genomic signature indications; collected clinical, pathological, treatment, and follow-up data.
- Utilized Oncotype DX, MammaPrint, and EndoPredict; risk calculated using MINDACT and Adjuvant Online.
Main Results
- Genomic signatures were used in 52.0% of patients.
- Treatment plans changed in 30.7% of cases based on genomic signature results.
- Chemotherapy was newly indicated for some patients and contraindicated for others, altering initial treatment strategies.
Conclusions
- Genomic signatures provide valuable information for tailoring adjuvant chemotherapy in breast cancer.
- These tests can refine treatment decisions, avoiding unnecessary chemotherapy or identifying patients who would benefit.
- The study highlights the clinical utility of genomic signatures in personalized breast cancer management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.